<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The combination of <z:chebi fb="0" ids="4031">Cyclosporin A</z:chebi> (CSA) and <z:chebi fb="0" ids="44185">Methotrexate</z:chebi> (MTX) is considered to be the standard regimen for the prevention of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) after stem cell transplantation (SCT) from HLA-identical siblings </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="168396">Mycophenolate</z:chebi> Mofetil (MMF) has been widely used for GVHD prophylaxis after nonmyeloablative SCT, but experience following myeloablative therapy is still limited </plain></SENT>
<SENT sid="2" pm="."><plain>We retrospectively compared CSA/MTX and CSA/MMF in 93 patients (median age 35 years, range 17-59 years, male subjects 48, female subjects 45) with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (n=33), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (n=3), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) (n=20) or <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n=37) who received CSA/MMF (n=26) or CSA/MTX (n=67) as GVHD prophylaxis following high-dose therapy and allogeneic SCT from HLA-identical siblings </plain></SENT>
<SENT sid="3" pm="."><plain>No statistically significant differences were found in overall survival, relapse rate, treatment-related mortality and <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="4" pm="."><plain>Time to myeloid recovery was significantly shorter in patients who received CSA/MMF </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that the combination of CSA/MMF appears equivalent to CSA/MTX for GVHD prophylaxis in patients receiving conventional-intensity SCT from HLA-identical siblings </plain></SENT>
</text></document>